Orange Book product · Generic (ANDA)
SUCRALFATE
SUCRALFATE
At a glance
Jul 23, 2024
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jul 23, 2024
1 yr 11 mo ago
Today
Pharmaceutical detail
Active ingredient
SUCRALFATE
Strength
1GM/10ML
Dosage form
SUSPENSION
Route
ORAL
TE code
Not listed
Application
ANDA 212769
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of SUCRALFATE
- 1993CARAFATEBrand (NDA)
NDA 019183 · ABBVIE
- —CARAFATEBrand (NDA)
NDA 018333 · ABBVIE
- 2026SUCRALFATEGeneric (ANDA)
ANDA 212141 · GLENMARK PHARMS LTD
- 2025SUCRALFATEGeneric (ANDA)
ANDA 211780 · PADAGIS US
- 2024SUCRALFATEGeneric (ANDA)
ANDA 217126 · COSETTE PHARMS NC
- 2024SUCRALFATEGeneric (ANDA)
ANDA 216474 · STRIDES PHARMA
- 2024SUCRALFATEGeneric (ANDA)
ANDA 216726 · ABON PHARMS LLC
- 2024SUCRALFATEGeneric (ANDA)
ANDA 213549 · PD PARTNERS
- 2023SUCRALFATEGeneric (ANDA)
ANDA 215705 · ZYDUS LIFESCIENCES
- 2022SUCRALFATEGeneric (ANDA)
ANDA 212913 · MYLAN
- 2022SUCRALFATEGeneric (ANDA)
ANDA 215576 · AMNEAL PHARMS
- 2022SUCRALFATEGeneric (ANDA)
ANDA 211884 · VISTAPHARM LLC
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
